

# Contents

<b>1</b>	<b>Introduction to Medication Effects on Male Reproduction</b>	<b>1</b>
<b>2</b>	<b>Challenges of Obtaining Evidence-Based Information Regarding Medications and Male Fertility</b>	<b>5</b>
2.1	Experimental Design	5
2.2	Species-Specificity and Reproductive Endpoints	7
2.3	Variation in Effects of Drugs in the Same Class	7
2.4	Few Studies with Live-Birth and Offspring Health as Outcomes	8
2.5	Individual Variation in Response	8
2.6	Illness Can Have Profound Effects on Male Reproductive Function	9
2.7	Mechanism of Toxicity Is Often Obscure	9
2.8	Drug Interactions in Humans Have Not Been Studied	9
<b>3</b>	<b>Male Reproductive Functions Disrupted by Pharmacological Agents</b>	<b>13</b>
3.1	Pre-testicular: The Hypothalamic–Pituitary–Gonadal (HPG) Axis	14
3.1.1	Endocrine Disrupting Chemicals	14
3.1.2	The Hypothalamus–Pituitary–Adrenal Axis and Corticosteroids	14
3.1.3	Sex Hormone Binding Globulin	15
3.1.4	Medications and Prolactin Levels	15
3.1.5	Medications and Thyroid Hormone Levels	17
3.2	Testicular: Spermatogenesis, Spermiogenesis, and Spermiation	18
3.3	Post-testicular: Epididymal Transit	18
3.4	Post-testicular: Ejaculation	19
3.4.1	Emission	20
3.4.2	Expulsion	20
3.4.3	Ejaculatory Dysfunction	21
3.5	Post-ejaculation Sperm Function	22
3.5.1	Sperm Transport in the Female Reproductive Tract	22
3.5.2	Fertilization and Offspring Health	23
3.6	Drug Metabolism	23

<b>4</b>	<b>Exogenous Androgens and Male Reproduction</b>	<b>25</b>
<b>5</b>	<b>Phosphodiesterase Inhibitors (PDE Inhibitors) and Male Reproduction</b>	<b>29</b>
5.1	Methylxanthines	32
5.2	Specific Phosphodiesterase Inhibitors	35
5.2.1	PDE5 and Male Reproduction	35
5.2.2	PDE5 Inhibitor Effects on Tissues In Vitro	36
5.2.3	PDE5 Inhibitor Effects on Testosterone Levels and Semen Quality in Humans	36
5.2.4	PDE5 Inhibitors in Experimental and Companion Species	37
<b>6</b>	<b>Pain Medications and Male Reproduction</b>	<b>39</b>
6.1	Opioids	39
6.1.1	Opioids and Testosterone Levels in Men	45
6.1.2	Opioids and Circulating PRL Levels	47
6.1.3	Pain Management in Men with Hypogonadism Desiring Fertility	48
6.1.4	The Endogenous Opioid System in Normal Male Reproduction	49
6.1.5	Opioids and Human Semen Quality	50
6.1.6	Opioids in Animal Models	50
6.2	Non-steroid Anti-inflammatory Drugs (NSAIDs)	52
6.2.1	NSAIDs and Human Male Reproduction	53
6.2.2	NSAIDs and Male Reproduction in Rodents	54
<b>7</b>	<b>5<math>\alpha</math>-Reductase Inhibitors (5ARIs) and Male Reproduction</b>	<b>59</b>
7.1	5ARIs and Testosterone Levels	60
7.2	5ARIs and Semen Quality	61
<b>8</b>	<b>Psychotropics and Male Reproduction</b>	<b>63</b>
8.1	Antidepressants	64
8.1.1	SSRIs	75
8.1.2	SNRIs, NRIs, NDRIs, Serotonergic and Melatonergic Antidepressants	78
8.1.3	TCAs	79
8.1.4	MAO Inhibitors	81
8.2	GABA <sub>A</sub> ergic Anxiolytics	82
8.2.1	Endocrine Effects of GABA <sub>A</sub> ergic Medications	83
8.2.2	GABA <sub>A</sub> ergic Medications, Spermatogenesis, and Semen	84
8.3	Antipsychotics	85
8.3.1	Antipsychotic Drugs and Increase in Peripheral PRL Levels	85
8.3.2	Antipsychotics and the HPG Axis	92
8.3.3	Antipsychotics and Ejaculatory Dysfunction	93
8.3.4	Antipsychotics and Semen Quality	95

8.3.5	Antipsychotic Medications in Experimental Animal Models . . . . .	95
8.3.6	Lithium . . . . .	97
8.4	Anticonvulsants . . . . .	98
8.4.1	Anticonvulsants and the HPG Axis . . . . .	98
8.4.2	Anticonvulsants and Semen Quality . . . . .	99
8.4.3	Anticonvulsant Medications in Experimental Animal Models . . . . .	100
<b>9</b>	<b>Cardiovascular/Pulmonary Medications and Male Reproduction . . . . .</b>	<b>103</b>
9.1	Adrenergic Drugs . . . . .	110
9.2	$\alpha$ -Adrenergic Agonists . . . . .	110
9.2.1	$\alpha$ -Adrenergic Agonists and In Vitro Studies of Male Reproductive Tract Tissue . . . . .	111
9.2.2	$\alpha$ -Adrenergic Agonists and the HPG Axis . . . . .	111
9.2.3	$\alpha$ -Adrenergic Agonists and Ejaculatory Dysfunction . . . . .	112
9.3	$\alpha$ -Adrenergic Antagonists ( $\alpha$ -Blockers) . . . . .	113
9.3.1	$\alpha$ -Adrenergic Antagonists and In Vitro Studies of Male Reproductive Tract Tissue . . . . .	113
9.3.2	$\alpha$ -Adrenergic Antagonists and the HPG Axis . . . . .	114
9.3.3	$\alpha$ -Adrenergic Antagonists and Human Ejaculatory Dysfunction . . . . .	114
9.3.4	$\alpha$ -Adrenergic Antagonists and Ejaculation in Other Species . . . . .	116
9.3.5	$\alpha$ -Adrenergic Antagonists and Semen Quality . . . . .	117
9.3.6	$\alpha$ -Adrenergic Antagonists and Fertility . . . . .	118
9.4	$\beta$ -Adrenergic Agonists . . . . .	118
9.5	$\beta$ -Adrenergic Antagonists ( $\beta$ -Blockers) . . . . .	119
9.6	Calcium Channel Blockers . . . . .	121
9.6.1	Calcium Channel Blockers and Human Male Reproduction . . . . .	121
9.6.2	Calcium Channel Blockers and Male Rat Reproduction . . . . .	123
9.7	Angiotensin Converting Enzyme (ACE) Inhibitors . . . . .	124
9.8	Diuretics . . . . .	126
9.8.1	Spironolactone . . . . .	126
9.8.2	Thiazide Diuretics . . . . .	129
9.9	Digoxin . . . . .	129
9.10	Hydralazine . . . . .	130
<b>10</b>	<b>Antimicrobials and Male Reproduction . . . . .</b>	<b>131</b>
10.1	Anti-parasitics . . . . .	142
10.2	Antifungals . . . . .	144
10.3	Antibacterials . . . . .	148
10.3.1	Aminoglycosides . . . . .	149
10.3.2	Amphenicols . . . . .	150
10.3.3	Cephalosporin Beta-Lactams . . . . .	150

10.3.4	Macrolides . . . . .	151
10.3.5	Nitrofurans . . . . .	152
10.3.6	Penicillin Beta-Lactams . . . . .	153
10.3.7	Polypeptides . . . . .	153
10.3.8	Fluoroquinolones . . . . .	153
10.3.9	Sulfonamides . . . . .	155
10.3.10	Tetracyclines . . . . .	156
10.4	Mixed Antimicrobials . . . . .	158
<b>11</b>	<b>Antivirals and Male Reproduction . . . . .</b>	<b>163</b>
11.1	HIV Infection Effects on Semen Quality . . . . .	169
11.2	Combination Antiretroviral Therapy (cART) Effect on Semen Quality . . . . .	171
11.3	Mitochondrial Inhibition with HIV Medications . . . . .	172
11.4	HIV Medication and the HPG Axis . . . . .	173
11.5	HIV Medication and Spermatogenesis/Semen Quality . . . . .	175
11.6	Purine Nucleoside Analogs . . . . .	176
11.7	Other Antivirals . . . . .	177
<b>12</b>	<b>Immunosuppressants and Male Reproduction . . . . .</b>	<b>179</b>
12.1	Corticosteroids . . . . .	186
12.1.1	Treatment of Antisperm Antibodies . . . . .	186
12.1.2	Treatment of Inflammatory Diseases . . . . .	187
12.1.3	Antirejection Treatment After Organ Transplant . . . . .	188
12.1.4	Studies in Healthy Men . . . . .	189
12.1.5	Studies in Non-human Primates . . . . .	190
12.1.6	Endocrine Studies in Rodents . . . . .	190
12.1.7	Spermatogenesis Studies in Rodents . . . . .	191
12.1.8	Studies in Domestic Species . . . . .	191
12.2	Cytostatics . . . . .	193
12.2.1	Azathioprine and 6-Mercaptopurine . . . . .	193
12.2.2	Methotrexate . . . . .	195
12.2.3	Chlorambucil . . . . .	197
12.2.4	Cyclophosphamide . . . . .	198
12.2.5	Melphalan . . . . .	201
12.3	Immunophilin Modulators . . . . .	201
12.3.1	Calcineurin Inhibitor Effects on the HPG Axis . . . . .	202
12.3.2	mTOR Inhibitor Effects on the HPG Axis . . . . .	203
12.3.3	Immunophilin Modulators in Male Rodents . . . . .	203
12.4	TNF- $\alpha$ Inhibitors . . . . .	206
12.5	Sulfasalazine . . . . .	206
<b>13</b>	<b>Miscellaneous Drugs and Male Reproduction . . . . .</b>	<b>211</b>
13.1	Cimetidine . . . . .	211
13.2	Colchicine . . . . .	217
13.3	Ergotamine . . . . .	218

13.4	Gastrokinetic Agents . . . . .	219
13.5	Hydroxyurea . . . . .	220
13.6	Metformin . . . . .	222
13.7	Mifepristone . . . . .	223
13.8	Propylthiouracil, Methimazole, Levothyroxine, Liothyronine . .	224
13.9	Retinoids . . . . .	224
13.10	Statins. . . . .	225
<b>References . . . . .</b>		<b>227</b>
<b>Index. . . . .</b>		<b>313</b>



<http://www.springer.com/978-3-319-69534-1>

Impacts of Medications on Male Fertility

Drobnis, E.; Nangia, A.K.

2017, XIII, 325 p., Hardcover

ISBN: 978-3-319-69534-1